Literature DB >> 19089973

Conserved amino acid networks involved in antibody variable domain interactions.

Norman Wang1, William F Smith, Brian R Miller, Dikran Aivazian, Alexey A Lugovskoy, Mitchell E Reff, Scott M Glaser, Lisa J Croner, Stephen J Demarest.   

Abstract

Engineered antibodies are a large and growing class of protein therapeutics comprising both marketed products and many molecules in clinical trials in various disease indications. We investigated naturally conserved networks of amino acids that support antibody V(H) and V(L) function, with the goal of generating information to assist in the engineering of robust antibody or antibody-like therapeutics. We generated a large and diverse sequence alignment of V-class Ig-folds, of which V(H) and V(L) domains are family members. To identify conserved amino acid networks, covariations between residues at all possible position pairs were quantified as correlation coefficients (phi-values). We provide rosters of the key conserved amino acid pairs in antibody V(H) and V(L) domains, for reference and use by the antibody research community. The majority of the most strongly conserved amino acid pairs in V(H) and V(L) are at or adjacent to the V(H)-V(L) interface suggesting that the ability to heterodimerize is a constraining feature of antibody evolution. For the V(H) domain, but not the V(L) domain, residue pairs at the variable-constant domain interface (V(H)-C(H)1 interface) are also strongly conserved. The same network of conserved V(H) positions involved in interactions with both the V(L) and C(H)1 domains is found in camelid V(HH) domains, which have evolved to lack interactions with V(L) and C(H)1 domains in their mature structures; however, the amino acids at these positions are different, reflecting their different function. Overall, the data describe naturally occurring amino acid networks in antibody Fv regions that can be referenced when designing antibodies or antibody-like fragments with the goal of improving their biophysical properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19089973     DOI: 10.1002/prot.22319

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  18 in total

1.  Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.

Authors:  Jianying Dong; Arlene Sereno; William B Snyder; Brian R Miller; Susan Tamraz; Adam Doern; Michael Favis; Xiufeng Wu; Hon Tran; Emma Langley; Ingrid Joseph; Antonio Boccia; Rebecca Kelly; Kathleen Wortham; Qin Wang; Lisa Berquist; Flora Huang; Sharon X Gao; Ying Zhang; Alexey Lugovskoy; Shelly Martin; Heather Gouvis; Steven Berkowitz; Gisela Chiang; Mitchell Reff; Scott M Glaser; Kandasamy Hariharan; Stephen J Demarest
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

Review 2.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

3.  Role of a noncanonical disulfide bond in the stability, affinity, and flexibility of a VHH specific for the Listeria virulence factor InlB.

Authors:  Matthew N Mendoza; Mike Jian; Moeko T King; Cory L Brooks
Journal:  Protein Sci       Date:  2020-02-08       Impact factor: 6.725

4.  Large-scale sequence and structural comparisons of human naive and antigen-experienced antibody repertoires.

Authors:  Brandon J DeKosky; Oana I Lungu; Daechan Park; Erik L Johnson; Wissam Charab; Constantine Chrysostomou; Daisuke Kuroda; Andrew D Ellington; Gregory C Ippolito; Jeffrey J Gray; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-25       Impact factor: 11.205

5.  Modulating non-native aggregation and electrostatic protein-protein interactions with computationally designed single-point mutations.

Authors:  C J O'Brien; M A Blanco; J A Costanzo; M Enterline; E J Fernandez; A S Robinson; C J Roberts
Journal:  Protein Eng Des Sel       Date:  2016-05-09       Impact factor: 1.650

6.  Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Authors:  Robert J Benschop; Chi-Kin Chow; Yu Tian; James Nelson; Barbra Barmettler; Shane Atwell; David Clawson; Qing Chai; Bryan Jones; Jon Fitchett; Stacy Torgerson; Yan Ji; Holly Bina; Ningjie Hu; Mahmoud Ghanem; Joseph Manetta; Victor J Wroblewski; Jirong Lu; Barrett W Allan
Journal:  MAbs       Date:  2019-06-10       Impact factor: 5.857

7.  Frontier of therapeutic antibody discovery: The challenges and how to face them.

Authors:  Zhi-Jian Lu; Su-Jun Deng; Da-Gang Huang; Yun He; Ming Lei; Li Zhou; Pei Jin
Journal:  World J Biol Chem       Date:  2012-12-26

8.  Identifying bottlenecks in transient and stable production of recombinant monoclonal-antibody sequence variants in Chinese hamster ovary cells.

Authors:  Megan Mason; Bernadette Sweeney; Katharine Cain; Paul Stephens; Susan T Sharfstein
Journal:  Biotechnol Prog       Date:  2012-05-21

9.  Rational engineering of antibody therapeutics targeting multiple oncogene pathways.

Authors:  Jonathan Fitzgerald; Alexey Lugovskoy
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 10.  Deep sequencing in library selection projects: what insight does it bring?

Authors:  J Glanville; S D'Angelo; T A Khan; S T Reddy; L Naranjo; F Ferrara; A R M Bradbury
Journal:  Curr Opin Struct Biol       Date:  2015-08       Impact factor: 6.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.